Data presented at Heart Rhythm 2026 has highlighted key therapies from Boston Scientific, including findings on the Farapulse PFA and Watchman LAAC devices. The data may have implications for the company's growth potential in electrophysiology and stroke care, although some studies have also raised concerns about rare fatal arrhythmias associated with certain devices. The presentation of this data appears to have had a positive impact on Boston Scientific's stock.